If you're looking into semaglutide for weight loss, the first thing most people Google after side effects is the price. The answer depends on which version you're taking, whether you have insurance, and how you're sourcing it. Brand-name Wegovy® at full list price is over $1,400 a month. Compounded semaglutide through telehealth can be under $200. This guide walks through every realistic option and what you'd actually pay.
Quick price reference
| Option | Typical monthly cost (no insurance) | Notes |
|---|---|---|
| Wegovy® (brand-name, weight loss label) | ~$1,400 | FDA-approved for weight loss; list price set by Novo Nordisk |
| Ozempic® (brand-name, diabetes label) | ~$1,030 | FDA-approved for type 2 diabetes (Novo Nordisk); also a semaglutide product |
| Compounded semaglutide (telehealth) | $150–$350 | Prepared by US-licensed compounding pharmacies |
| Pallas Health (compounded injection) | $199 every 4 weeks | All-inclusive: medication + provider + shipping; first month lower |
| Rybelsus® (oral semaglutide) | ~$990 | Daily tablet form; type 2 diabetes label |
| Pallas Health (Wegovy® pill, brand-name tablet) | $299 first month | Then $499 every 4 weeks; FDA-approved for chronic weight management; cash-pay, not billed to insurance |
Prices shift — Novo Nordisk adjusts list pricing; telehealth brands reprice frequently. These are representative as of early 2026.
Why there's such a huge gap
The price gap between $1,400 brand-name Wegovy® and compounded semaglutide at $199 every 4 weeks reflects very different products and regulatory pathways. Compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Three structural factors drive most of the price difference:
1. Patent and regulatory costs. Novo Nordisk spent over a decade and billions of dollars developing, testing, and getting FDA approval for semaglutide. Wegovy®'s price reflects the need to recoup those costs and fund research for the next drug. Compounded versions don't go through the same FDA approval process — they're prepared per-prescription by US-licensed compounding pharmacies under state pharmacy board oversight.
2. Manufacturing and supply. Brand-name Wegovy® comes in prefilled injection pens, manufactured in sterile facilities, shipped through a national distribution network. Compounded semaglutide is prepared in smaller batches by compounding pharmacies, typically shipped in vials with syringes. The overhead is dramatically lower.
3. Insurance infrastructure. Brand-name drug pricing assumes most patients will be covered through insurance, where Novo Nordisk negotiates rebates with pharmacy benefit managers. The "list price" and the "net price insurance pays" are often very different — but if you're uninsured, you pay close to list. Compounded semaglutide through telehealth skips the insurance middle entirely.
The one-line version
Brand-name pricing reflects FDA approval costs, manufacturing infrastructure, and insurance-rebate economics. Compounded telehealth operates under a different regulatory framework with a different cost base — and a different evidentiary base. Compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality.
Brand-name pricing, unpacked
Wegovy® (semaglutide 2.4 mg, weight loss indication)
- List price: $1,402.98/month (as of 2026)
- With commercial insurance coverage: $0–$150/month depending on plan
- With a Novo Nordisk savings card (commercial insurance required): as low as $0/month for the first 2 years, capped benefit
- Without insurance: close to list price
Wegovy® coverage for weight loss is still inconsistent. Most commercial plans exclude anti-obesity medications entirely, and Medicare is legally prohibited from covering them. This is the single most common reason patients move to compounded options.
Ozempic® (semaglutide 0.5–2 mg, diabetes indication)
- List price: ~$1,030/month
- With Medicare Part D (if prescribed for diabetes): typically $35–$200/month
- With commercial insurance (for type 2 diabetes): often well-covered; coverage for off-label weight loss use is inconsistent
- Without insurance: close to list price
Some patients have a provider prescribe Ozempic® off-label for weight loss, hoping for better coverage. This works sometimes — but many plans now require a diabetes diagnosis code for Ozempic® coverage.
Oral semaglutide (Rybelsus® and the Wegovy® pill)
- Rybelsus® list price: ~$990/month; type 2 diabetes label, lower weight-loss figures than the injection in its own trials, and usually prescribed for diabetes rather than weight loss
- The Wegovy® pill (25 mg semaglutide tablets, FDA-approved December 2025 for chronic weight management): Novo Nordisk's self-pay offer starts at $149/month for the 1.5 mg starting dose; in OASIS 4, adults on the 25 mg tablet lost an average of 13.6% of body weight at 64 weeks versus 2.4% on placebo
- Through Pallas: the Wegovy® pill is $299 for your first month, then $499 every 4 weeks, cash-pay, not billed to insurance, prescribed when a clinician judges it appropriate
Compounded semaglutide pricing
Compounded versions are prepared by US-licensed compounding pharmacies on a per-patient basis when a licensed prescriber documents a specific clinical need. The semaglutide and tirzepatide shortages that once drove most compounding have since been resolved (semaglutide on February 21, 2025; tirzepatide on December 19, 2024), so a compounded GLP-1 prescription is no longer based on shortage status — it requires a documented patient-specific clinical-difference rationale under FDCA §503A(b)(1)(C). Pricing alone is not a permitted basis.
Typical compounded pricing through telehealth platforms:
| Platform | Entry price | Ongoing |
|---|---|---|
| Pallas Health | $139 first month | $199 every 4 weeks |
| Ro Body membership | $39 first month | $149/mo membership; medication billed separately |
| Hims & Hers | $199 first month | $299/mo |
| Henry Meds | From $179/mo | Varies by medication and dose; medication included |
| Mochi Health | $39 first month | $79/mo membership; compounded semaglutide from $60/mo on top |
Pallas's first month is $139, and the plan then renews every 4 weeks at the price above. Quarterly, 6-month and annual plans lower the average (from $179/mo on the quarterly plan). Nothing is charged at checkout — the first month is charged only once a clinician prescribes. Pallas terms in full: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Some platforms include the medication, provider visit, shipping, and ongoing messaging in one plan price; others bill a membership and the medication separately, so compare the all-in monthly total rather than the headline number. Competitor figures above are as published on each company's own pricing page on September 24, 2026, and change often.
What insurance actually covers in 2026
This is the most confusing part of GLP-1 pricing. Here's the practical breakdown:
Medicare (65+)
Medicare Part D is prohibited by federal law from covering medications prescribed solely for weight loss. Wegovy® and Zepbound® are not covered for obesity. Ozempic® and Mounjaro® can be covered for type 2 diabetes.
There is an exception as of 2024: Medicare Part D plans can cover Wegovy® if prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and obesity — but plans are not required to, and coverage is inconsistent.
There is also a separate, temporary federal program — the Medicare GLP-1 Bridge — that covers Wegovy® and Zepbound® for obesity at a $50 copay for eligible Part D enrollees from July 1 to December 31, 2026, ahead of a planned multi-year demonstration beginning in 2027. It runs outside the standard Part D benefit and has its own eligibility rules, so confirm whether you qualify.
Medicaid
Varies by state. Some Medicaid programs cover weight-loss GLP-1s (e.g., Virginia, North Carolina); many do not. Call your state Medicaid office to confirm before starting.
Commercial insurance (employer plans, individual marketplace)
- About 25–30% of commercial plans cover weight-loss GLP-1s in 2026, though coverage is expanding
- Most plans require prior authorization — proof of BMI 30+ (or 27+ with comorbidity), documented prior attempt at lifestyle intervention, and a prescription from a provider in your network
- Step therapy is common — plans may require you to try older, cheaper weight loss medications first
- Self-funded employer plans (most Fortune 500 employers) often specifically exclude weight-loss medications, even if the underlying carrier technically covers them
What to actually do
- Call the number on the back of your insurance card
- Ask: "Do you cover Wegovy® or Zepbound® for weight loss? What's my cost share, and what prior authorization is required?"
- If covered: get the prior auth form, have your provider complete it, submit, expect a 1–2 week decision
- If not covered: this is where compounded telehealth becomes the practical alternative
The real total cost of brand-name therapy
Even when brand-name Wegovy® is covered, patients often pay meaningful out-of-pocket costs. A realistic annual budget:
Year 1 with commercial insurance covering Wegovy®:
- Medication copay: $25–$150/month × 12 = $300–$1,800
- Provider visits: $0–$200 (varies by plan)
- Labs (baseline + annual): $100–$400
- Total: ~$400–$2,400
Year 1 without insurance (cash pay brand-name):
- Medication: $1,400/month × 12 = $16,800
- Provider visits (cash PCP): $150–$400
- Total: ~$17,000+
Year 1 compounded telehealth (Pallas):
- $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime.
- Total: about $2,500 for year one — the first month plus twelve 4-week renewals, all-inclusive, nothing charged until a clinician prescribes
The gap between uninsured brand-name and compounded telehealth is roughly $14,500/year at current pricing. For most patients without coverage, compounded is the only economically viable option.
Hidden costs to watch for
When evaluating any option, make sure these are accounted for:
- Dose escalation — Wegovy®, compounded, and Ozempic® all titrate up over 4–5 months. Some pharmacies charge more at higher doses; others don't. Ask.
- Refill lags — if a pharmacy is delayed, you may pay out of pocket for a partial emergency fill elsewhere
- Prior auth denials — about 30% of initial Wegovy® prior auth requests are denied. You can appeal, but plan for it
- Medication breaks — if you stop the medication, weight typically returns within 6–12 months per the STEP 4 extension data. Some patients end up paying for two rounds if they stop prematurely
- Lab work — some telehealth programs include baseline and follow-up labs; others don't. Cash lab work is $100–$300
Which option is right for your budget
Commercial insurance covers Wegovy®: Use it. Even with copay, brand-name with full pharmacy support is generally the most reliable option.
Commercial insurance doesn't cover weight-loss GLP-1s, but covers Ozempic® for diabetes: If you genuinely qualify for Ozempic® (documented type 2 diabetes), this may be the cheapest path. Don't misrepresent your condition — insurance fraud is a real legal exposure and providers won't prescribe without documentation.
No insurance coverage for any GLP-1: Compounded telehealth is a practical option. At roughly $2,500/year all-in, it's about 15% of the cost of cash-pay brand-name. Compounded medications are not FDA-approved products and are not generic versions of brand-name drugs.
Medicare, no cardiovascular indication: Compounded telehealth. Medicare Part D won't cover Wegovy®, and paying cash for brand-name at retirement budgets is rarely realistic.
Looking to switch from brand-name to compounded: Talk to your provider about continuity. Most telehealth platforms can match your current dose and continue therapy seamlessly. Read our guide on compounded vs brand-name GLP-1 for the clinical differences.
Frequently asked questions
Is compounded semaglutide a generic version of Wegovy® or Ozempic®? No. Compounded semaglutide is not a generic of any FDA-approved product. There is no FDA-approved generic semaglutide on the US market — semaglutide is under patent. Compounded medications are prepared per-prescription by US-licensed compounding pharmacies and are legally and regulatorily distinct from FDA-approved generic drugs. Compounded products are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
Can I use HSA or FSA funds for semaglutide? Yes, typically. Semaglutide prescribed by a licensed provider is an eligible medical expense for HSA and FSA accounts. Most telehealth platforms provide receipts suitable for reimbursement. Check with your plan administrator to confirm specific rules.
Now that the semaglutide shortage is resolved, can pharmacies still compound it? Yes — but on a narrower basis. With the shortage resolved (semaglutide on February 21, 2025; tirzepatide on December 19, 2024), compounding is no longer justified by shortage status. A compounded GLP-1 prescription now requires a documented patient-specific clinical-difference rationale under FDCA §503A(b)(1)(C) — for example, an intolerance to an inactive ingredient in the FDA-approved product or a need for a non-standard dose. Pricing or convenience alone is not a permitted basis, and compounded availability can change on relatively short notice.
Why is Wegovy® more expensive than Ozempic®? Wegovy® and Ozempic® are both Novo Nordisk products containing semaglutide as the active ingredient, but they have different dose ceilings and different FDA-approved indications. Wegovy® goes up to 2.4 mg/week and is FDA-approved for chronic weight management; Ozempic® goes up to 2.0 mg/week and is FDA-approved for type 2 diabetes. Insurance companies price these indications differently.
Does Pallas require insurance? No. Pallas plans are cash-pay only — no insurance processing. This is what lets us keep pricing flat and all-in on compounded semaglutide injection: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Patients can separately submit receipts to HSA/FSA accounts.
Will compounded pricing stay this low? Unclear. With the shortage resolved, compounded GLP-1s are dispensed on a per-patient clinical-need basis, so availability is narrower than it was at the peak of the shortage. If Novo Nordisk lowers Wegovy®'s list price or expands its self-pay programs (which it has signaled interest in doing), the gap narrows. For now, the cost difference between cash-pay brand-name and compounded telehealth remains large.
Bottom line: If insurance covers Wegovy®, use it. If not, compounded telehealth is a practical alternative at a fraction of cash-pay brand-name cost — note that compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Pallas compounded semaglutide injection is one all-in plan price: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That's roughly $2,400 for year one vs $17,000 for uninsured brand-name.
